CD19 and diffuse large B-cell lymphoma: Findings from the JULIET and TRANSCEND NHL-001 trials indicate that approximately 27%–47% of patients with R/R DLBCL exhibit primary resistance to CD19-directed CAR-T therapy (5, 6), and 30–50% relapse after initial remission (7).